Advancing Medical Research at Novartis Pavillon: Del-brax Phase I/II Study Results
The public exhibition and event space on the Novartis Campus continues to bridge complex science and public understanding. Visitors exploring the institution's offerings can gain insight into cutting-edge breakthroughs, such as recent clinical developments in neuroscience and rare genetic conditions.
Exploring Medical Innovation and Scientific Research in Basel
The ongoing scientific developments highlighted by the acquisition of specialized platforms reflect a broader commitment to advanced therapeutics. Among these advancements, the FORTITUDE Phase I/II clinical trial evaluating delpacibart braxlosiran (del-brax) for facioscapulohumeral muscular dystrophy (FSHD) met its primary and key secondary biomarker endpoints.
These findings demonstrated reductions in KHDC1L and creatine kinase levels, pointing to target engagement and decreased muscle damage. As a potential disease-modifying treatment for a condition affecting thousands across the US and EU, the investigational therapy continues its evaluation through ongoing trial phases, including the FORTITUDE Phase I/II study (NCT05747924) and the FORTITUDE-3 Phase III study (NCT07038200).
What Visitors Experience Through Scientific Displays
For those interested in the future of healthcare and drug development, visiting the exhibition centre offers a closer look at how modern research transforms laboratory discoveries into clinical solutions. Through immersive programs, guests can better understand the complexities of genetic conditions and the rigorous journey of pharmaceutical innovation.
To plan your visit and discover more about current exhibits and scientific displays at Musemap (musemap.art), take a look at the museums list, check out the interactive map, or explore what's on exhibitions.
